It is believed the lenacapavir shot could end HIV/Aids in the country within 14 to 18 years if enough people were to take it.

South Africa has become the first African country — and our medicines regulator the third worldwide — to register the ...

South Africa has welcomed a U.S. bridging plan worth $115 million to continue funding HIV treatment and prevention programs ...

Through a US$ 29 million grant, South Africa will receive enough medicine to provide HIV prevention to 450 000 people at high ...

The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...

With millions of South Africans affected by both HIV/AIDS and mental health challenges, leading experts have come together at ...

South Africa has become the first African country, and our medicines regulator the third worldwide, to register the ...

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool against the disease.

One in ten clinics in South Africa — across 22 health districts in six provinces — could start to hand out a twice-a-year anti-HIV jab as early as February if the country’s medicines regulator ...

The Health departmental officials said that “a new plan will be shared" for when the funding ends in March 2026.

South Africa has become the first African country to register lenacapavir, a groundbreaking six-monthly HIV prevention ...

In response, the South African National Treasury allocated R750 million in emergency funding to prevent service interruptions ...